These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29043783)

  • 1. Marine Mammal Microbiota Yields Novel Antibiotic with Potent Activity Against Clostridium difficile.
    Ochoa JL; Sanchez LM; Koo BM; Doherty JS; Rajendram M; Huang KC; Gross CA; Linington RG
    ACS Infect Dis; 2018 Jan; 4(1):59-67. PubMed ID: 29043783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial and antibiotic potentiating activities of tropical marine sponge extracts.
    Beesoo R; Bhagooli R; Neergheen-Bhujun VS; Li WW; Kagansky A; Bahorun T
    Comp Biochem Physiol C Toxicol Pharmacol; 2017 Jun; 196():81-90. PubMed ID: 28392375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase.
    Singh SB
    Bioorg Med Chem; 2016 Dec; 24(24):6291-6297. PubMed ID: 27143131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural products as a source of drug leads to overcome drug resistance.
    Silver LL
    Future Microbiol; 2015; 10(11):1711-8. PubMed ID: 26517443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut bacteria of animals/pests living in polluted environments are a potential source of antibacterials.
    Akbar N; Siddiqui R; Sagathevan KA; Khan NA
    Appl Microbiol Biotechnol; 2019 May; 103(10):3955-3964. PubMed ID: 30941460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An In Vitro Model of the Human Colon: Studies of Intestinal Biofilms and Clostridium difficile Infection.
    Crowther GS; Wilcox MH; Chilton CH
    Methods Mol Biol; 2016; 1476():223-34. PubMed ID: 27507345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical communication in the gut: Effects of microbiota-generated metabolites on gastrointestinal bacterial pathogens.
    Vogt SL; Peña-Díaz J; Finlay BB
    Anaerobe; 2015 Aug; 34():106-15. PubMed ID: 25958185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies.
    Gil F; Calderón IL; Fuentes JA; Paredes-Sabja D
    Future Microbiol; 2018 Mar; 13():469-482. PubMed ID: 29464969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools.
    Mamo G
    Adv Biochem Eng Biotechnol; 2016; 156():433-464. PubMed ID: 27432247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.
    Gil F; Paredes-Sabja D
    Future Microbiol; 2016 Sep; 11():1179-89. PubMed ID: 27546386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binaphthyl-1,2,3-triazole peptidomimetics with activity against Clostridium difficile and other pathogenic bacteria.
    Wales SM; Hammer KA; King AM; Tague AJ; Lyras D; Riley TV; Keller PA; Pyne SG
    Org Biomol Chem; 2015 May; 13(20):5743-56. PubMed ID: 25901416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.
    Winston JA; Theriot CM
    Anaerobe; 2016 Oct; 41():44-50. PubMed ID: 27163871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Metabolites from Marine Micromonospora: Chemistry and Bioactivities.
    Qi S; Gui M; Li H; Yu C; Li H; Zeng Z; Sun P
    Chem Biodivers; 2020 Apr; 17(4):e2000024. PubMed ID: 32100940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial substances produced by pathogen inhibitory gut bacteria in Labeo rohita: Physico-chemical characterization, purification and identification through MALDI-TOF mass spectrometry.
    Mukherjee A; Banerjee G; Mukherjee P; Ray AK; Chandra G; Ghosh K
    Microb Pathog; 2019 May; 130():146-155. PubMed ID: 30826430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New
    Back CR; Stennett HL; Williams SE; Wang L; Ojeda Gomez J; Abdulle OM; Duffy T; Neal C; Mantell J; Jepson MA; Hendry KR; Powell D; Stach JEM; Essex-Lopresti AE; Willis CL; Curnow P; Race PR
    Mar Drugs; 2021 Feb; 19(2):. PubMed ID: 33670308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile Infection: A Model for Disruption of the Gut Microbiota Equilibrium.
    Blanchi J; Goret J; Mégraud F
    Dig Dis; 2016; 34(3):217-20. PubMed ID: 27028327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiosemicarbazones active against Clostridium difficile.
    Costello C; Karpanen T; Lambert PA; Mistry P; Parker KJ; Rathbone DL; Ren J; Wheeldon L; Worthington T
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1708-11. PubMed ID: 18243694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of surotomycin for the treatment of Clostridium difficile.
    Knight-Connoni V; Mascio C; Chesnel L; Silverman J
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):195-204. PubMed ID: 26670919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.